Eurofins CDMO Alphora Inc., a contract development and manufacturing organization (CDMO), has recently taken a significant leap in its operational capabilities. The company has unveiled a new Active Pharmaceutical Ingredient (API) manufacturing facility in Mississauga, Canada. This expansion
The biopharma sector is facing a significant wave of layoffs in 2024, affecting thousands of employees across various companies. This trend is shaped by numerous internal and external factors, including corporate restructuring, market adaptations, strategic divestments, and cost-saving measures.
Catalent, a prominent contract development and manufacturing organization (CDMO), has announced the divestment of its Somerset, New Jersey, oral solids development and small-scale manufacturing facility to Ardena, a Belgian CDMO. This transaction marks Ardena's entry into the U.S. market and
The market for gene therapies is predicted to surge from $9 billion in 2023 to $23.9 billion in 2028, according to MarketsandMarkets. With such rapid growth, it has become increasingly evident that having an effective analytical testing strategy is crucial for the successful development and
Eli Lilly is making a bold move to shape the future of pharmaceutical manufacturing with its $4.5 billion investment in the Lilly Medicine Foundry. This new facility, set to open in late 2027 in Lebanon, Indiana's LEAP Research and Innovation District, is poised to redefine how the industry
Wilson County, located in Eastern North Carolina, has recently become a hotspot for significant economic development, largely driven by substantial investments from pharmaceutical giants. Within the past eight days, the region has received promises of major funding, hinting at a promising future
